Dendritic cell vaccines targeting survivin in head and neck cancer.

abstract：:FOCIS goes South: Advances in Translational and Clinical Immunology was the first Federation of Clinical Immunology Societies (FOCIS) ( www.focisnet.org ) meeting held in Latin America (May 15-17, 2017, Santiago de Chile, Chile). The meeting was organized as a 3-day workshop and was fostered by the Millennium Institut...

journal_title：Immunotherapy

authors： Kalergis AM,Anegon I,González PA

更新日期：2017-09-01 00:00:00

abstract：:Background: Severe pneumonia and acute respiratory distress syndrome (ARDS) due to COVID-19 is a challenge for nowadays medical practice. Although there is no clarity in the principal mechanism of lung damage and ARDS development, it has been suggested that one of the main reasons of this pathology is the hyperactivat...

journal_title：Immunotherapy

authors： Cala-García JD,Sierra-Bretón JD,Cavelier-Baiz JE,Faccini-Martínez ÁA,Pérez-Díaz CE

更新日期：2020-10-01 00:00:00

abstract：:Evaluation of: Boudousq V, Ricaud S, Garambois V et al.: Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing (125)I-labeled monoclonal antibodies. J. Nucl. Med. 51, 1748-1755 (2010). Mesothelioma, pseudomyxoma peritonei, ovarian and colon cancers, and s...

journal_title：Immunotherapy

authors： Baranowska-Kortylewicz J

更新日期：2011-04-01 00:00:00

abstract：:Tumor-associated macrophages (TAMs), representing most of the leukocyte population in solid tumors, demonstrate great phenotypic heterogeneity and diverse functional capabilities under the influence of the local tumor microenvironment. These anti-inflammatory and protumorigenic macrophages modulate the local microenvi...

journal_title：Immunotherapy

authors： Petty AJ,Yang Y

更新日期：2017-03-01 00:00:00

abstract：:Evaluation of: Rech AJ, Mick R, Martin S et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patents. Sci. Transl. Med. 4(134), 134ra62 (2012). Tregs are involved in the maintenance of immunological self-tolerance. Recent studies have revealed that Tregs ...

journal_title：Immunotherapy

authors： Morita R,Hirohashi Y,Sato N

更新日期：2012-11-01 00:00:00

abstract：:Lactobacilli are a group of normal microbiota whose immunomodulatory effects have been known for a long time. Recently, they have gained more attention for their direct and indirect effects on cancer cells. Several cell line experiments, animal model studies as well as clinical trials have indicated their inhibitory e...

journal_title：Immunotherapy

authors： Abedin-Do A,Taherian-Esfahani Z,Ghafouri-Fard S,Ghafouri-Fard S,Motevaseli E

更新日期：2015-01-01 00:00:00

abstract：AIM:This multicenter randomized placebo-controlled double-blind clinical trial investigated which maintenance dose shows the optimal benefit-risk ratio for subcutaneous immunotherapy with a Dermatophagoides pteronyssinus allergoid preparation. OBJECTIVE:To evaluate four maintenance doses of the allergoid preparation v...

journal_title：Immunotherapy

authors： Jutel M,Rudert M,Kreimendahl F,Kuna P

更新日期：2018-09-01 00:00:00

abstract：:Evaluation of: Savoldo B, Ramos CA, Liu E et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121(5), 1822-1826 (2011). Chimeric antigen receptor (CAR)-T cells are promising antitumor immunotherapies. However, there are limit...

journal_title：Immunotherapy

authors： Gandhi M,Jones K

更新日期：2011-12-01 00:00:00

abstract：:There has been growing evidence that heat-shock protein (HSP) functions as an endogenous immunomodulator for innate and adaptive immune responses. Since HSPs inherently act as chaperones within cells, passive release (e.g., by cell necrosis) and active release (including release by secretion in the form of an exosome)...

journal_title：Immunotherapy

authors： Tamura Y,Torigoe T,Kukita K,Saito K,Okuya K,Kutomi G,Hirata K,Sato N

更新日期：2012-08-01 00:00:00

abstract：:Mycobacterium tuberculosis was one of the first human pathogens to be identified as the cause of a specific disease--TB. TB was also one of the first specific diseases for which immunotherapy was attempted. In more than a century since, multiple different immunotherapies have been attempted, alongside vaccination and ...

journal_title：Immunotherapy

authors： Doherty TM

更新日期：2012-06-01 00:00:00

abstract：:Aim: To explore the value of rate of cancer progression (ROP) prior to starting PD-1 inhibitors as a predictive and prognostic biomarker. Materials & methods: Retrospective data of patients with metastatic non-small-cell lung cancer treated with second-line PD-1 inhibitors were collected. Patients were divided into tw...

journal_title：Immunotherapy

authors： Prasanna T,Arasaratnam M,Boyer M,McNeil C,Barnet MB,Asher R,Hui R,Nagrial A,Kao S

更新日期：2019-06-01 00:00:00

abstract：:Sarcoidosis is a systemic disease with an incidence of 1 to 40 per 100 000 persons per year. It predominantly affects people in the age of 20 to 40 years old. Disease course varies from mild self-limiting to chronic debilitating and life-threatening disease. Since the cause of sarcoidosis is unknown, curative therapy ...

journal_title：Immunotherapy

authors： Crommelin HA,Vorselaars AD,van Moorsel CH,Korenromp IH,Deneer VH,Grutters JC

更新日期：2014-01-01 00:00:00

abstract：:Immunotherapy strategies for cancer are focused on inducing effective and specific cytotoxic responses mediated by CD8 T cells. On the other hand, immunosuppressive mechanisms induced by the tumor, such as the generation of tumor-specific CD4(+)CD25(+)FoxP3(+) Tregs, conspire against the efficacy of immunotherapies. I...

journal_title：Immunotherapy

authors： Muccioli M,Longstaff C,Benencia F

更新日期：2012-05-01 00:00:00

abstract：:Evaluation of: Davila ML, Riviere I, Wang X et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6(224), 224ra25 (2014). Recently, chimeric antigen receptor (CAR) T-cell immunotherapy has entered clinical trials in patients with relapsed or refr...

journal_title：Immunotherapy

authors： Patel JM,Dale GA,Vartabedian VF,Dey P,Selvaraj P

更新日期：2014-01-01 00:00:00

abstract：:Despite novel chemotherapy treatments, pancreatic ductal adenocarcinoma (PDA) remains a lethal disease. New targeted cancer vaccines may represent a viable option for patients with PDA. The Wilms' tumor 1 (WT1) antigen is one of the most widely expressed tumor-associated antigens in various types of tumors, including ...

journal_title：Immunotherapy

authors： Koido S,Okamoto M,Shimodaira S,Sugiyama H

更新日期：2016-11-01 00:00:00

abstract：:Systemic lupus erythematosus is a systemic autoimmune disease characterized by the presence of myriad autoantibodies, some with pathogenic potential, and diverse clinical manifestations. Involvement of the kidney is a major cause of morbidity and mortality in human lupus patients and in murine models of the disease. I...

journal_title：Immunotherapy

authors： Tagoe C,Putterman C

更新日期：2012-04-01 00:00:00

abstract：:The neonatal phase is a transitory period characterized by an absence of memory cells, favoring a slow adaptive response prone to tolerance effects and the development of Th2-type responses. However, when appropriately stimulated, neonates may achieve an immune response comparable with adult counterparts. One strategy...

journal_title：Immunotherapy

authors： de Brito CA,Goldoni AL,Sato MN

更新日期：2009-09-01 00:00:00

abstract：:Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that infiltrate human and experimental tumors and strongly inhibit anticancer immune response directly or by inducing regulatory T-lymphocyte activity. Consequently, MDSCs are important actors of cancer-induced immune tolerance and a major obstacle to...

journal_title：Immunotherapy

authors： Martin F,Apetoh L,Ghiringhelli F

更新日期：2012-01-01 00:00:00

abstract：:Non-coding RNAs (ncRNAs) are an abundant component of the human transcriptome. Their biological role, however, remains incompletely understood. Nevertheless, ncRNAs are highly associated with cancer development and progression due to their ability to modulate gene expression, protein translation and growth pathways. I...

journal_title：Immunotherapy

authors： Shek D,Read SA,Akhuba L,Qiao L,Gao B,Nagrial A,Carlino MS,Ahlenstiel G

更新日期：2020-05-01 00:00:00

abstract：:HER2/neu is expressed in the majority of in situ breast cancers, but maintained in 20-30% of invasive breast cancer (IBC). During breast tumorigenesis, there is a progressive loss of anti-HER2 CD4(pos) Th1 (anti-HER2Th1) from benign to ductal carcinoma in situ, with almost complete loss in IBC. This anti-HER2Th1 respo...

journal_title：Immunotherapy

authors： De La Cruz LM,Nocera NF,Czerniecki BJ

更新日期：2016-10-01 00:00:00

abstract：:Background: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has emerged as a powerful immunotherapy in relapsed or refractory B-cell acute lymphoblastic leukemia. The changes in extramedullary (EM) disease in pediatric relapsed or refractory B-cell acute lymphoblastic leukemia after CAR T-cell therapy hav...

journal_title：Immunotherapy

authors： Huang J,Rong L,Wang E,Fang Y

更新日期：2021-01-01 00:00:00

abstract：:The dysfunctional immune response that characterizes systemic lupus erythematosus (SLE) associates with an unbalanced production of soluble mediators that are crucial in promoting and sustaining chronic inflammation. The successful use of biologics in several autoimmune diseases has led to studies in SLE aimed at cont...

journal_title：Immunotherapy

authors： La Cava A

更新日期：2010-07-01 00:00:00

abstract：:Aim: To evaluate the long-term efficacy of sublingual immunotherapy (SLIT) in treating mite-sensitized allergic rhinitis (AR). Materials & methods: 150 AR children were randomly divided into SLIT and pharmacotherapy (PT) groups, receiving a 3-year course of SLIT along with PT or PT only. Results: The symptom and medic...

journal_title：Immunotherapy

authors： Chen WB,Shen XF,Li Q,Zhou WC,Cheng L

更新日期：2020-08-01 00:00:00

abstract：:Evaluation of: Pujol-Autonell I, Ampudia RM, Monge P et al. Immunotherapy with tolerogenic dendritic cells alone or in combination with rapamycin does not reverse diabetes in NOD mice. ISRN Endocrinol. doi:10.1155/2013/346987 (2013) (Epub ahead of print). Many reports confirm that dendritic cells (DCs) can prevent aut...

journal_title：Immunotherapy

authors： Giannoukakis N

更新日期：2013-06-01 00:00:00

abstract：:The poor prognosis of pancreatic cancer patients signifies a need for radically new therapeutic strategies. Tumor-targeted oncolytic viruses have emerged as attractive therapeutic candidates for cancer treatment due to their inherent ability to specifically target and lyse tumor cells as well as induce antitumor effec...

journal_title：Immunotherapy

authors： Al Yaghchi C,Zhang Z,Alusi G,Lemoine NR,Wang Y

更新日期：2015-01-01 00:00:00

abstract：:In recent years, nanoparticulate-mediated drug delivery research has examined a full spectrum of nanoparticles that can be used in diagnostic and therapeutic cancer applications. A key aspect of this technology is in the potential to specifically target the nanoparticles to diseased cells using a range of molecules, i...

journal_title：Immunotherapy

authors： Fay F,Scott CJ

更新日期：2011-03-01 00:00:00

abstract：:Aim: To evaluate treatment results in advanced/metastatic melanoma patients treated with anti-PD-1 immunotherapy in routine practice in oncology centers in Poland. Methods: Multicenter retrospective analysis included 499 patients with unresectable/metastatic (stage IIIC-IV) melanoma treated with anti-PD-1 in first-lin...

journal_title：Immunotherapy

authors： Cybulska-Stopa B,Pacholczak-Madej R,Kamińska-Winciorek G,Ziętek M,Czarnecka AM,Piejko K,Galus Ł,Ziółkowska B,Kieszko S,Kempa-Kamińska N,Calik J,Rolski J,Sałek-Zań A,Gajewska-Wicher K,Drosik-Kwaśniewska A,Rogala P,Kubiatow

更新日期：2021-03-01 00:00:00

abstract：:Renal toxicity from immune checkpoint inhibitors (ICIs) is an increasingly recognized cause of acute kidney injury among patients with cancer. ICI-associated acute kidney injuries typically present as acute interstitial nephritis and the timing of onset is highly variable. Herein, we present a case of a patient with r...

journal_title：Immunotherapy

authors： Mulroy M,Ghafouri S,Sisk A,Ribas A,Goshtaseb R,Cherry G,Shen J

更新日期：2021-03-01 00:00:00

abstract：:After the first wave of the tsunami of immune checkpoint inhibitors, 2016 was marked by the second wave, revealed by numerous US FDA approvals, publications and abstracts in relation with these drugs in different cancers and settings. First, we reported all new indications of anti-CTLA4, anti-programmed cell death pro...

journal_title：Immunotherapy

authors： Kourie HR,Awada G,Awada A

更新日期：2017-06-01 00:00:00

abstract：:Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients & methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/O...

journal_title：Immunotherapy

authors： Moreau P,Hebraud B,Facon T,Leleu X,Hulin C,Hashim M,Hu Y,Caillot D,Benboubker L,Zweegman S,Merz M,Weisel K,Salwender H,Mai EK,Goldschmidt H,Bertsch U,Vanquickelberghe V,Kampfenkel T,Boer C,Krotneva S,Proskorovsky

更新日期：2021-02-01 00:00:00